Table 4 Association between change in HbA1c at 6 months and SMBG frequency in the telemonitoring group.

From: Impact of initial active engagement in self-monitoring with a telemonitoring device on glycemic control among patients with type 2 diabetes

 

Crude

Model 1

Model 2

Model 3

β (95% CI)

p

β (95% CI)

p

β (95% CI)

p

β (95% CI)

p

SMBG frequency (days per week)

 Total

−0.444 (−0.760–−0.128)

0.006

−0.502 (−0.842–−0.163)

0.004

−0.522 (−0.862–−0.183)

0.003

−0.676 (−0.933–−0.420)

<0.001

 Week 1 to 6

−0.458 (−0.744–−0.173)

0.002

−0.492 (−0.790–−0.195)

0.001

−0.626 (−0.841–−0.410)

<0.001

−0.444 (−0.889–−0.442)

<0.001

 Week 6 to 24

−0.311 (−0.619–−0.002)

0.048

−0.364 (−0.704–−0.023)

0.037

−0.493 (−0.746–−0.239)

<0.001

−0.498 (−0.763–−0.233)

<0.001

SMBG frequency (days per week)

 Total

−0.263 (−0.410–−0.116)

0.001

−0.308 (−0.463–−0.153)

<0.001

−0.353 (−0.464–−0.241)

<0.001

−0.367 (−0.485–−0.249)

<0.001

 Week 1 to 6

−0.263 (−0.397–−0.130)

<0.001

−0.295 (−0.433–−0.157)

<0.001

−0.330 (−0.427–−0.232)

<0.001

−0.352 (−0.455–−0.250)

<0.001

 Week 6 to 24

−0.178 (−0.314–−0.041)

0.012

−0.211 (−0.358–−0.064)

0.005

−0.241 (−0.352–−0.130)

<0.001

−0.247 (−0.365–−0.129)

<0.001

  1. Model 1 is adjusted for age and sex.
  2. Model 2 is adjusted for age, sex, and baseline self-efficacy scale.
  3. Model 3 is adjusted for age, sex, self-efficacy scale, BMI, SBP, LDL, and HbA1c at baseline.